CH622270A5 - Process for the preparation of polyhalosteroids - Google Patents
Process for the preparation of polyhalosteroids Download PDFInfo
- Publication number
- CH622270A5 CH622270A5 CH841579A CH841579A CH622270A5 CH 622270 A5 CH622270 A5 CH 622270A5 CH 841579 A CH841579 A CH 841579A CH 841579 A CH841579 A CH 841579A CH 622270 A5 CH622270 A5 CH 622270A5
- Authority
- CH
- Switzerland
- Prior art keywords
- chlorine
- diene
- pregna
- methyl
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft ein Verfahren zur Herstellung neuer polyhalogenierten 11 ß, 17 a-Dihydroxy-16 a-methyl-pregna-l,4-dien-3,20-dion-17-ester der Formel flV The invention relates to a process for the preparation of new polyhalogenated 11β, 17 a-dihydroxy-16 a-methyl-pregna-l, 4-diene-3,20-dione-17-ester of the formula flV
HO. >\ 5^3 HO. > \ 5 ^ 3
Cl Cl
M M
\ ^\l/ï\ / \ / *. \ ^ \ l / ï \ / \ / *.
• 1 • • 1 •
' *'*0Ac '*' * 0Ac
(i) (i)
I I X I S \f \ / I I X I S \ f \ /
'CIL 'CIL
15 worin X Chlor oder Fluor, X' Brom oder insbesondere Chlor, und Ac eine von einer Carbonsäure abgeleitete Acylgruppe darstellt. 15 wherein X represents chlorine or fluorine, X 'bromine or especially chlorine, and Ac represents an acyl group derived from a carboxylic acid.
Die genannte Acylgruppe Ac leitet sich von den in der Steroidchemie gebräuchlichen Carbonsäuren mit 1-18 C-20 Atomen, insbesondere von niederaliphatischen Mono- oder Dicarbonsäuren mit 1-7 C-Atomen, wie z.B. von der Essigsäure, Buttersäure, Isobuttersäure, Valeriansäure, Isovalerian-säure, Trimethylessigsäure, Hexansäure, Heptansäure und vor allem der Propionsäure, ab. Man kann aber auch Säuren ver-25 wenden, welche ungesättigt, verzweigt, und/oder in üblicher Weise substituiert sind, wie z.B.: Diäthylessigsäure, 2,2- oder 3,3-Dimethylbuttersäure, Phenyl und Cyclohexylessigsäure, Phenoxyessigsäure, Cyclopentylpropionsäure, Halogenessigsäuren, Aminoessigsäure, Oxypropionsäure, Benzoesäure oder 30 Undecylensäure. The acyl group Ac mentioned is derived from the carboxylic acids with 1-18 C-20 atoms customary in steroid chemistry, in particular from lower aliphatic mono- or dicarboxylic acids with 1-7 C atoms, such as e.g. on acetic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, trimethylacetic acid, hexanoic acid, heptanoic acid and especially propionic acid. However, it is also possible to use acids which are unsaturated, branched and / or substituted in the customary manner, such as, for example: diethyl acetic acid, 2,2- or 3,3-dimethylbutyric acid, phenyl and cyclohexylacetic acid, phenoxyacetic acid, cyclopentylpropionic acid, haloacetic acids, Amino acetic acid, oxypropionic acid, benzoic acid or 30 undecylenic acid.
Die Verbindungen der Formel I besitzen wertvolle pharmakologische Eigenschaften, wodurch sie zur Anwendung als Therapeutika geeignet sind. So zeichnen sie sich durch eine hervorragende antiinflammatorische Wirksamkeit bei lokaler 35 Applikation aus, wobei im Verhältnis dazu ihre systemische (zentrale) Wirkung bemerkenswert niedrig ist, wie sich im Tierversuch nachweisen lässt. Wegen dieser günstigen Verteilung der biologischen Eigenschaften sind diese Verbindungen in der Medizin in allen Indikationen verwendbar, die für Glu-40 cocorticoid-Analoga mit entzündungshemmenden Eigenschaften vorgesehen sind, insbesondere aber als lokal anzuwendende antiinflammatorische Glucocorticoide. Besonders hervorzuheben sind 17-NiederaIkylcarbonsäureester sowohl des 21-Brom-2-chlor-6a,9a-difluor-llß,17a-dihydroxy-16a-me-45 thyl-pregna-l,4-dien-3,20-dions und 21-Brom-2,9a-dichlor-6cc-fluor-llß,17a-dihydroxy-16a-methyl-pregna-l,4-dien-3,20-dions und 2,9a,21-Trichlor-6a-fluor-llß,17a-dihydroxy-16a-methyl-pregna-l,4-dien-3,20 dions, welche z.B. in Roh-wattegranulomtest an der Ratte im Dosisbereich von 0.003 bis so 0.3 mg/Pellet bei lokaler Applikation antiinflammatorisch wirksam sind. Bei gleicher Versuchsanordnung sind die ersten Zeichen einer systemischen Wirkung, wie sie durch die Abnahme des Körper- und insbesondere des Nebennieren-und Thymus-Gewichts feststellbar ist, erst oberhalb der Dosis ss von 0.3 mg/Pellet merklich. So weist z.B. im erwähnten Roh-wattegranulomtest an der Ratte bei lokaler Verabreichung, wobei der zu implantierende Rohwattepressling direkt mit dem Steroid imprägniert wird, das 2,21-Dichlor-6a,9a-difluor-11 ß, 17cx-dihydroxy-16a-methyI-pregna-1,4-dien-3,20-dion-60 17-propionat eine ausgeprägte antünflammatorische Wirkung bereits bei einer Dosis von 0.01 mg/Pellet auf. The compounds of formula I have valuable pharmacological properties, which makes them suitable for use as therapeutic agents. They are characterized by excellent anti-inflammatory activity when applied locally, although their systemic (central) effect is remarkably low in comparison, as can be demonstrated in animal experiments. Because of this favorable distribution of the biological properties, these compounds can be used in medicine in all indications which are intended for Glu-40 cocorticoid analogs with anti-inflammatory properties, but in particular as locally applicable anti-inflammatory glucocorticoids. Particularly noteworthy are 17-lower alkyl carboxylic acid esters of both 21-bromo-2-chloro-6a, 9a-difluoro-11ß, 17a-dihydroxy-16a-me-45 thyl-pregna-l, 4-dien-3,20-dions and 21 -Brom-2,9a-dichloro-6cc-fluoro-11ß, 17a-dihydroxy-16a-methyl-pregna-1, 4-diene-3,20-dions and 2,9a, 21-trichloro-6a-fluoro-11ß , 17a-dihydroxy-16a-methyl-pregna-l, 4-diene-3.20 dions, which e.g. in the raw wattegranuloma test on the rat in the dose range from 0.003 to 0.3 mg / pellet with local application are anti-inflammatory. With the same experimental arrangement, the first signs of a systemic effect, as can be determined by the decrease in body and in particular adrenal and thymus weight, are noticeable only above the dose ss of 0.3 mg / pellet. For example, in the above-mentioned raw wategranuloma test on the rat when administered locally, the raw cotton compact to be implanted being directly impregnated with the steroid, the 2,21-dichloro-6a, 9a-difluoro-11β, 17cx-dihydroxy-16a-methyI-pregna- 1,4-diene-3,20-dione-60 17-propionate has a pronounced anti-inflammatory effect even at a dose of 0.01 mg / pellet.
Die Verbindungen der Formel I können zudem als wertvolle Zwischenprodukte für die Herstellung anderer nützlicher Stoffe, insbesondere anderer pharmakologisch wirksamer 65 Steroide, Anwendung finden. The compounds of the formula I can also be used as valuable intermediates for the preparation of other useful substances, in particular other pharmacologically active steroids.
Die Verbindungen der Formel (I) werden erfindungsgemäss hergestellt, indem man eine Verbindung der allgemeinen Formel The compounds of formula (I) are prepared according to the invention by using a compound of general formula
CHX' CHX '
I 2 • CH^ CO / \l I I 2 • CH ^ CO / \ l I
M ?%£*> « , \ M?% £ *> «, \
Cl • | • • (TT} Cl • | • • (TT}
V VK V V '--CH ' V VK V V '--CH'
III 3 III 3
• • • •
^ \ / \ / ^ \ / \ /
0 • ! 0 •!
• •
F F
worin Ac und X' die für die Formel I angegebenen Bedeutungen haben, mit einem Halogenwasserstoff HX, worin X Chlor oder Fluor bedeutet, oder mit einem den Halogenwasserstoff HX abgebenden Mittel behandelt. wherein Ac and X 'have the meanings given for the formula I, treated with a hydrogen halide HX, where X is chlorine or fluorine, or with an agent which gives off the hydrogen halide HX.
Gemäss dem erfindungsgemässen Verfahren lässt man in an sich bekannter Weise Chlorwasserstoff oder Fluorwasserstoff auf die 9ß,llß-Oxidogruppe der Ausgangsverbindungen der Formel (II) einwirken, wobei man zweckmässig einen wasserfreien Halogenwasserstoff, gegebenenfalls in einem indifferenten Lösungsmittel, wie Chloroform, Tetrahydrofuran oder insbesondere Dimethylformamid, oder auch wässrige Fluorwasserstoffsäure verwendet. Man kann auch Verbindungen verwenden, die Chlor- bzw. Fluorwasserstoff abgeben, wie z.B. die Salze dieser Säuren mit einer tertiären organischen Base, z.B. Pyridin, oder Lewis-Salze und ähnliche Additions Verbindungen der Fluorwasserstoffsäure. Ein besonders günstiges Verfahren ist im US-Patent Nr. 3 211 758 beschrieben und beansprucht, wonach man Fluorwasserstoffsäure in Form eines Adduktes mit einem Carbaminsäure- oder Thiocarbaminsäure-Derivat, insbesondere mit Harnstoff, zur Anwendung bringt. According to the process of the invention, hydrogen chloride or hydrogen fluoride is allowed to act on the 9β, 11ß-oxido group of the starting compounds of the formula (II) in a manner known per se, expediently using an anhydrous hydrogen halide, optionally in an inert solvent such as chloroform, tetrahydrofuran or in particular dimethylformamide , or also used aqueous hydrofluoric acid. It is also possible to use compounds which release hydrogen chloride or hydrogen fluoride, e.g. the salts of these acids with a tertiary organic base, e.g. Pyridine, or Lewis salts and similar addition compounds of hydrofluoric acid. A particularly favorable process is described and claimed in US Pat. No. 3,211,758, according to which hydrofluoric acid is used in the form of an adduct with a carbamic acid or thiocarbamic acid derivative, in particular with urea.
Die für die Ausführung der erfindungsgemässen Verfahrensmethode nötigen Ausgangsstoffe können in an sich bekannter Weise hergestellt werden. The starting materials necessary for carrying out the process method according to the invention can be prepared in a manner known per se.
Die gemäss der vorliegenden Erfindung erhaltenen Endstoffe können mit Vorteil der Herstellung von pharmazeutischen Präparaten zur Anwendung in der Human- oder Veterinärmedizin dienen, welche die neuen, oben beschriebenen pharmakologisch wirksamen Stoffe der Formel I als aktive Substanzen zusammen mit einem pharmazeutischen Trägermateria] enthalten. The end products obtained according to the present invention can advantageously be used to produce pharmaceutical preparations for use in human or veterinary medicine which contain the new pharmacologically active substances of the formula I described above as active substances together with a pharmaceutical carrier material].
In den folgenden Beispielen wird die Temperatur in Celsiusgraden angegeben. In the following examples the temperature is given in degrees Celsius.
Beispiel 1 example 1
In einem Kunststoffgefäss wird 1,5 g 2,21-Dichlor-6a-fluor-9ß, 11 ß-epoxy-17 a-hydroxy-16a-methyl-pregna-1,4-dien- 1.5 g of 2,21-dichloro-6a-fluoro-9β, 11β-epoxy-17a-hydroxy-16a-methyl-pregna-1,4-diene is placed in a plastic vessel.
622 270 622 270
3,20-dion-17-propionat mit 30 ml eines Reagens, zubereitet durch Vermischen von 20 g Harnstoff mit 26,5 g wasserfreiem flüssigem Fluorwasserstoff, Übergossen und während 3 Stunden unter Eiskühlung gerührt. Das Reaktionsgemisch wird auf 115 ml eiskalte gesättigte Ammoniak-Lösung gegossen, mit Essigsäure schwach angesäuert und zweimal mit Chloroform extrahiert. Die organischen Phasen werden vereinigt, mit eiskalter verdünnter Natronlauge gewaschen, getrocknet und am Wasserstrahlvakuum eingedampft. Das Rohprodukt wird über eine lOOfache Gewichtsmenge Kieselgel (Stufensäule) chromatographiert. Die mit einem Gemisch von Toluol-Essig-ester (95:5) eluierten Fraktionen ergeben, aus Methylenchlorid/Äther umkristallisiert, das 2,21-Dichlor-6a,9a-difluor-11 ß,17 a-dihydroxy-16 a-methyl-pregna-l,4-dien-3,20-dion-17-propionat, Smp. 242°. 3,20-dione-17-propionate with 30 ml of a reagent, prepared by mixing 20 g of urea with 26.5 g of anhydrous liquid hydrogen fluoride, poured over and stirred for 3 hours under ice-cooling. The reaction mixture is poured onto 115 ml of ice-cold saturated ammonia solution, slightly acidified with acetic acid and extracted twice with chloroform. The organic phases are combined, washed with ice-cold dilute sodium hydroxide solution, dried and evaporated in a water jet vacuum. The crude product is chromatographed over a 100-fold amount by weight of silica gel (step column). The fractions eluted with a mixture of toluene-ethyl acetate (95: 5), recrystallized from methylene chloride / ether, give 2,21-dichloro-6a, 9a-difluoro-11β, 17 a-dihydroxy-16 a-methyl -pregna-l, 4-diene-3.20-dione-17-propionate, mp. 242 °.
Beispiel 2 Example 2
In eine Lösung von 1,3 g 2,21-Dichlor-6a-fluor-9ß,l lß-epoxy-17a~hydroxy-16a-methyl-pregna-l,4-dien-3,20-dion-propionat in 65 ml Chloroform wird während 30 Minuten bei 0° Chlorwasserstoffgas eingeleitet. Das Gemisch wird weitere 30 Minuten bei 0° stehen gelassen, mit Chloroform verdünnt, mit einer eiskalten gesättigten Natriumhydrogencarbonat-Lö-sung gewaschen, getrocknet und im Vakuum eingedampft. Das erhaltene Rohprodukt wird an 100-facher Gewichtsmenge Silicagel (Stufensäule) chromatographiert. Das gewünschte Produkt wird mit einem 99:1-Gemisch von Toluol-Methanol eluiert. Nach Kristallisation aus Methylenchlorid-Äther erhält man 2,9a,21-Trichlor-6<x-fluor-llß,17a-dihydroxy-16a-methyl-pregna-l,4-dien-3,20-dion-17-propionat, Smp. 260-261". In a solution of 1.3 g of 2,21-dichloro-6a-fluoro-9ß, lß-epoxy-17a ~ hydroxy-16a-methyl-pregna-l, 4-diene-3,20-dione-propionate in 65 ml of chloroform is introduced for 30 minutes at 0 ° hydrogen chloride gas. The mixture is left to stand at 0 ° for a further 30 minutes, diluted with chloroform, washed with an ice-cold saturated sodium hydrogen carbonate solution, dried and evaporated in vacuo. The crude product obtained is chromatographed on 100 times the amount by weight of silica gel (step column). The desired product is eluted with a 99: 1 mixture of toluene-methanol. After crystallization from methylene chloride ether, 2,9a, 21-trichloro-6 <x-fluoro-11ß, 17a-dihydroxy-16a-methyl-pregna-l, 4-diene-3,20-dione-17-propionate is obtained, M.p. 260-261 ".
Beispiel 3 Example 3
In der im Beispiel 1 beschriebenen Weise wird 21-Brom-2-chlor-6 a-fluor-9 ß, 11 ß-epoxy-17 a-hydroxy-16 a-methyl-preg-na-l,4-dien-3,20-dion-17-propionat zum 21-Brom-2-chlor-6 a,9 a-difluor-11 ß, 17 a-dihydroxy-16 a-methyl-pregna-1,4-dien-3,20-dion-17-propionat umgewandelt. Smp. 236° (Zersetzung) nach Umkristallisation aus Methylenchlorid-Äther. In the manner described in Example 1, 21-bromo-2-chloro-6 a-fluoro-9β, 11β-epoxy-17 a-hydroxy-16 a-methyl-preg-na-l, 4-dien-3 , 20-dione-17-propionate to 21-bromo-2-chloro-6 a, 9 a-difluoro-11 ß, 17 a-dihydroxy-16 a-methyl-pregna-1,4-diene-3.20- dion-17-propionate converted. Mp 236 ° (decomposition) after recrystallization from methylene chloride ether.
Beispiel 4 Example 4
In der im Beispiel 1 beschriebenen Weise wird 2,21-Di-chlor-6 a-fluor-9 ß, 11 ß-epoxy-17 a-hydroxy-16 a-methyl-preg-na-l,4-dien-3,20-dion-17-valerianat mit dem Fluorierungsrea-gens zum amorphen 2,21-Dichlor-6a,9a-difluor-llß,17a-dihydroxy-16 a-methyl-pregna-1,4-dien-3,20-dion-17 - valeria-nat umgewandelt. In the manner described in Example 1, 2,21-di-chloro-6 a-fluoro-9β, 11β-epoxy-17 a-hydroxy-16 a-methyl-preg-na-l, 4-dien-3 , 20-dione-17-valerianate with the fluorinating agent to give the amorphous 2,21-dichloro-6a, 9a-difluoro-11ß, 17a-dihydroxy-16 a-methyl-pregna-1,4-diene-3.20- dion-17 - valeria-nat converted.
3 3rd
s s
10 10th
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
B B
Claims (7)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1615175A CH621801A5 (en) | 1975-12-12 | 1975-12-12 | Process for the preparation of polyhalosteroids |
Publications (1)
Publication Number | Publication Date |
---|---|
CH622270A5 true CH622270A5 (en) | 1981-03-31 |
Family
ID=4414846
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1615175A CH621801A5 (en) | 1975-12-12 | 1975-12-12 | Process for the preparation of polyhalosteroids |
CH841579A CH622270A5 (en) | 1975-12-12 | 1979-09-18 | Process for the preparation of polyhalosteroids |
CH841679A CH622271A5 (en) | 1975-12-12 | 1979-09-18 | Process for the preparation of polyhalosteroids |
CH841479A CH621802A5 (en) | 1975-12-12 | 1979-09-18 | Process for the preparation of polyhalosteroids |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1615175A CH621801A5 (en) | 1975-12-12 | 1975-12-12 | Process for the preparation of polyhalosteroids |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH841679A CH622271A5 (en) | 1975-12-12 | 1979-09-18 | Process for the preparation of polyhalosteroids |
CH841479A CH621802A5 (en) | 1975-12-12 | 1979-09-18 | Process for the preparation of polyhalosteroids |
Country Status (4)
Country | Link |
---|---|
BE (1) | BE849268A (en) |
CH (4) | CH621801A5 (en) |
SE (1) | SE423903B (en) |
ZA (1) | ZA767382B (en) |
-
1975
- 1975-12-12 CH CH1615175A patent/CH621801A5/en not_active IP Right Cessation
-
1976
- 1976-12-10 ZA ZA767382A patent/ZA767382B/en unknown
- 1976-12-10 SE SE7613920A patent/SE423903B/en not_active IP Right Cessation
- 1976-12-10 BE BE173138A patent/BE849268A/en not_active IP Right Cessation
-
1979
- 1979-09-18 CH CH841579A patent/CH622270A5/en not_active IP Right Cessation
- 1979-09-18 CH CH841679A patent/CH622271A5/en not_active IP Right Cessation
- 1979-09-18 CH CH841479A patent/CH621802A5/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SE423903B (en) | 1982-06-14 |
BE849268A (en) | 1977-06-10 |
ZA767382B (en) | 1977-11-30 |
CH622271A5 (en) | 1981-03-31 |
CH621802A5 (en) | 1981-02-27 |
CH621801A5 (en) | 1981-02-27 |
SE7613920L (en) | 1977-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT363201B (en) | METHOD FOR PRODUCING NEW 9ALPHA, 21-DIHALOGEN-11BETA, 17ALPHA-DIHYDROXY-6ALPHA- | |
DE2707336A1 (en) | NEW ANDROSTADIEN-17-CARBONIC ACID ESTER | |
CH625809A5 (en) | Process for the preparation of polyhalogenated steroids | |
CH622270A5 (en) | Process for the preparation of polyhalosteroids | |
EP0077541B1 (en) | Delta-1,3,5-3-chloro-11 beta, 16 alpha, 17 alpha, 21-tetrahydroxy-pregnan-20-one-16,17-acetonide derivatives, process for their preparation and pharmaceutical preparations containing them | |
DE1793600A1 (en) | Process for making steroid compounds | |
CH643864A5 (en) | 16,17-PYRAZOLINO AND 16,17-ISOPYRAZOLINO-1, 4-PREGNADIEN DERIVATIVES. | |
EP0440752A1 (en) | Method for the preparation of 3-desoxy-4-ene steroids. | |
EP0063368B1 (en) | Process for the preparation of pregn-4-ene-3,20-dione derivatives and 17-alpha-ethynyl-17-beta-trifluoroacetoxy-gon-4-ene-3-one derivatives, and pharmaceutical compositions containing the latter compounds | |
CH626633A5 (en) | ||
AT246342B (en) | Process for the production of new halogenated 16-methylene steroids | |
DE881945C (en) | Process for the production of therapeutically valuable alcohols of the cyclopentanopolyhydrophenanthrene series | |
DE1468632C (en) | öalpha Acetylthio 4 en 3 on steroids and process for their production | |
DE1904586A1 (en) | 16alpha-alkyl steroids | |
AT258487B (en) | Process for the production of new 6 α -methyl-16-fluoromethylene steroids | |
DE1145170B (en) | Process for the preparation of 9,11-oxidosteroids of the androstane and pregnane series | |
DE1097440B (en) | Process for the production of í¸- or í¸-3-keto steroids of the pregnan and androstane series | |
DE1189547B (en) | Process for the preparation of therapeutically active steroid compounds | |
CH505809A (en) | 5,10-Seco steroids of the androstane and pregnane series (I) Where S is an androstane or pregnane residue and the molecule may be further subst. and more | |
DE1046044B (en) | Process for the preparation of 11ª ‰, 17ª ‡ -Dioxy-21-fluoro-1,4-pregnadiene-3,20-dione and 17ª ‡ -oxy-21-fluoro-1,4-pregnadiene-3,11,20-trione | |
DE1123321B (en) | Process for the preparation of therapeutically active steroid compounds | |
DE1113453B (en) | Process for the production of substitution products of Reichsteins-Substance-S or their 21-acylates | |
DE1193041B (en) | Process for making delta 7, delta 7.9, (11), delta 7.9, (11), 16, delta 7, delta 8 or delta 8.16 steroids | |
DE1126866B (en) | Process for the preparation of 21-fluorosteroids of the pregnane series | |
CH356767A (en) | Method of making steroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |